drugset / Trial / NCT02225886

Ascorbic Acid Administration in the Treatment of Anemia in Chronic Hemodialysed Patients

NCT02225886

Phase 4 Unknown 100 enrolled Anemia Working Group Romania
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The administration of ascorbic acid seemed to increase the iron available for erythropoiesis, thus improving the anemia response to the treatment. The investigators therefore aimed to evaluate the effects of intravenous ascorbic acid administration in hemodialysed patients with iron overload.

Timeline

Start
2020-02-01
Primary completion
2023-03
Completion
2023-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Vitamin C Other / unclassified 300 mg Intravenous

Indications